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Data obtained from peptide mapping of the active and inactive forms of human renin show that there are 
extensive regions of common sequence in the two forms of the enzyme, and are consistent with the hypothe- 
sis that inactive renin is a renin zymogen. 
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1. INTRODUCTION 
Renin’(EC 3.4.99.19) is a highly specific aspartic 
proteinase which is synthesized mainly in the jux- 
taglomerirlar cells of the afferent glomerular 
arteriole, of the kidney. It is released from the 
kidney into the circulation where it cleaves the 
cuz-globulin angiotensinogen to produce the inac- 
tive decapeptide angiotensin I. Subsequently, 
angiotensin I is cleaved by a peptidyl dipeptide 
hydrolase (converting enzyme) to give the vasoac- 
tive octapeptide, angiotensin II, which has 
numerous actions concerned with sodium and fluid 
homeostasis and with the maintenance of blood 
pressure [ 1,2]. 
and thus the possibility that human inactive renin 
is a complex of active renin with a renin inhibitor 
could not be excluded. 
We have recently purified microgram quantities 
of inactive renin from human renal cortex and 
shown that it consists of a single polypeptide chain 
[la]. As expected for a renin zymogen, human in- 
active renin (Mr 48000) is slightly larger than the 
active form of the enzyme (iK 40000) and can be 
activated by limited proteolysis. We report direct 
evidence obtained from peptide mapping that the 
active and inactive forms of renin are structurally 
related. 
Many proteins are synthesized as inactive 
precursors or zymogens which are subsequently 
converted to their active forms by limited pro- 
teolysis. This is true for a large number of ex- 
tracellular proteinases including pepsin and 
chymosin, the best characterised of the aspartic 
proteinases [3]. Recently, it has become apparent 
that renin is also synthesized as a precursor [4-81. 
2. MATERIALS AND METHODS 
2.1. Reagents 
In man, an inactive form of renin is present both 
within the kidney and in the circulation [g-12]. 
Although this form of the enzyme has been called 
prorenin, little evidence has been presented to 
show that it is actually a biosynthetic precursor of 
renin. In extracts of some animal kidneys, renin is 
associated with a ‘renin-binding protein’ [ 13- 151 
Chemicals and other materials were obtained 
either from the sources described in the ap- 
propriate references or from BDH Chemicals, 
Poole, Dorset, except for the following: bovine 
serum albumin (BSA), aldolase, pyruvate kinase 
and carbonic anhydrase were from Boehringer 
(London), Lewes, Sussex; ovalbumin, & 
lactoglobulin, and Bohon-Hunter reagent (N- 
succinimidyl-3-(4-hydroxyphenyl)propionate) w re 
from Sigma, Poole; V8 proteinase from 
Staphylococcus aureus was from Miles 
Laboratories, Stoke Poges, Slough; labelled 
Bolton-Hunter reagent (N-succinimidyl-3-(4-hy- 
Published by Elsevier Science Publishers B. V. 
00145793/84/%3.00 0 1984 Federation of European Biochemical Societies 439 
Volume 175, number 2 FEBS LETTERS October 1984 
droxy-5-[‘251]iodophenyl)propionate; 2000 Ci/ 
mmol) was from Amersham International, Bucks. 
Active and inactive renin were purified from 
human renal cortex as described previously 
[16,17]. 
2.2. Polyacrylamide gel electrophoresis (PAGE) 
Electrophoresis in the presence of 0.1% (w/v) 
sodium dodecyl sulphate (SDS) was carried out us- 
ing the method of [18]. 
2.3. Radiolabelling of proteins 
Samples (2~68) of active renin, inactive renin, 
and a mixture of standard proteins (0.4 /cg each of 
pyruvate kinase, ovalbumin, aldolase, carbonic 
anhydrase and&lactoglobulin), dissolved in 100 pl 
of 80 mM triethanolamine/HCl (pH 8.5)/2% 
(w/v) SDS, were heated at 100°C in a boiling water 
bath for 3 min and then cooled to 4°C. 1 pg of 
each protein sample (50~1) was reacted with 
300 pmol of labelled Bolton-Hunter reagent. In 
each case, the reagent (600 PCi), dissolved in 50 pl 
of benzene/0.2% (v/v) dimethylformamide, was 
pipetted into a small glass vial (5 x 15 mm) and 
then dried by evaporation of the solvent at room 
temperature under a flow of nitrogen. The sample 
was added to the dried reagent and the reaction 
mixture shaken for 30 min at 4’C. The reaction 
mixture was then transferred to a second glass vial 
containing 10 pmol of unlabelled Bolton-Hunter 
reagent and shaken for a further 30 min at 4°C. In 
order to prevent the subsequent labelling of carrier 
proteins, unchanged Bolton-Hunter reagent was 
reacted with 50 pl of 100 mM Tris/HCl (pH 8.5) 
for 10 min at 4°C. Finally, 100,ul of 100 mM 
Tris/HCl (pH 8.5), containing 200 pg BSA as car- 
rier protein, was added to the mixture. 
2.4. Purification of labelled proteins 
The labelled proteins were separated from the 
other labelled products of the acylation reaction 
(acylated Tris and 3-(4-hydroxyd-[‘251]iodophen- 
yl)propionic acid) by precipitation with 1 ml of ice- 
cold 10% (w/v) trichloroacetic acid. In each case, 
the precipitated protein was allowed to stand for 
15 min on ice and was then collected by centrifuga- 
tion at 1000 x g and 4°C for 5 min. Each preci- 
pitate was washed with 1 ml of ice-cold 10% (w/v) 
trichloroacetic acid and then with 2 x 1 ml of ice- 
cold acetone. 
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The labelled proteins were further purified by 
PAGE in the presence of 0.1% (w/v) SDS. Each 
protein precipitate was dissolved in 50 ,~l of sample 
buffer (72.5 mM Tris/HCl (pH 6.8)/3% (w/v) 
SDS/lo% (v/v) glycerol/5% (v/v) 2-mercapto- 
ethano1/0.002% (w/v) bromophenol blue), and 
electrophoresis carried out using polyacrylamide 
rod gels (5 mm diameter; 3% stacking gel, 10% 
resolving gel). After electrophoresis, the gels were 
frozen using powdered dry ice. Each gel was sliced 
into 1 mm segments and the segments counted for 
1251 
Labelled proteins were eluted from the 
polyacrylamide gel by crushing the appropriate gel 
segments with a glass rod and incubating the gel 
fragments for 24 h at 4°C with 300 pl of 100 mM 
ammonium bicarbonate/O.01 % (w/v) BSA (elu- 
tion buffer). In each case, the gel slurry was then 
poured into a 1 ml disposable pipette tip contain- 
ing glass wool and the liquid separated from the gel 
fragments by centrifugation for 2 min at 500 rpm 
in a benchtop centrifuge. The gel slurry was rinsed 
with a further 200 pl of elution buffer and cen- 
trifuged again for 2 min at 500 rpm. The com- 
bined eluates containing the labelled proteins were 
then frozen and stored at -20°C. 
2.5. Peptide mapping by analysis of V8 proteinase 
digests using high-performance liquid 
chromatography (HPLC) 
HPLC solvents were argon degassed for each ex- 
periment. Trifluoroacetic acid (0.1070, w/v) was 
filtered through a 0.2 pm Millipore filter. 
Samples (200000 cpm) of labelled active and in- 
active renin in 200 ~1 of 100 mM ammonium 
bicarbonate/O.01 @/o (w/v) BSA were exhaustively 
digested by incubation with 5 ,ul of V8 proteinase 
solution (1 mg/ml in 100 mM ammonium bicar- 
bonate) for 24 h at 37°C and then with a further 
5 pl of the proteinase solution for 6 h at 37°C. 
Analysis of the protein digests was carried out 
using a Gilson model 303 computer controlled gra- 
dient pumping HPLC system (Scotlab, Bellshill, 
Scotland) fitted with a PBondapak Cls reverse- 
phase column (Waters, Hartford). Each protein 
digest was lyophilised and resuspended in 25 ,ul 
0.1% (w/v) trifluoroacetic acid. 20 ~1 of this solu- 
tion was applied to the column using a valve loop 
injector and the chromatogram developed over 
80 min using a O-40% gradient of isopropanol in 
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0.1% (w/v) trifluoroacetic acid at a flow rate of 
1 ml/min. 300-/rl fractions were collected and 
counted for iz51. 
3. RESULTS 
Standard microscale peptide mapping techni- 
ques involving the detection of resolved peptides 
using ninhydrin or fluorescamine generally require 
milligram quantities of protein as starting material 
[ 191. Since only microgram quantities of the active 
and inactive forms of renin were available for com- 
parison by peptide mapping, it was necessary to 
label the proteins using radioiodinated Bolton- 
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Fig.1. SDS-PAGE of radiolabelled proteins. Fig.2. HPLC analysis of V8 proteinase digests of the 
Discontinuous electrophoresis was carried out in rod gels active and inactive forms of renin. V8 proteinase digests 
(stacking gel, 3% polyacrylamide; resolving gel, 10% of “‘1-1abelled active and inactive renin (approx. 
polyacrylamide). After electrophoresis was complete, 170000 cpm of each preparation) were analysed by 
the gels were sliced into l-mm segments and the HPLC. Each digest, dissolved in 20~1 of 0.1% (w/v) 
segments then counted for “‘1. A, labelled active renin trifluoroacetic acid, was applied to a ,uBondapak Cis 
preparation; B, labelled inactive renin preparation; C, reverse-phase column and the chromatogram developed 
labelled standard M, proteins: PK, pyruvate kinase over 80 min using a O-40% gradient of isopropanol in 
(57000); OV, ovalbumin (43000); A, aldolase (40000); 0.1% (w/v) trifluoroacetic acid at a flow rate of 
CA, carbonic anhydrase (29000); &LG, fi-lactoglobulin 1 ml/min. 30021 fractions were collected and counted 
(17500). for 12sI. 
Hunter reagent. This reagent labels both lysine and 
terminal amino groups [ZO]. 
The labelled proteins were separated from other 
labelled products of the reaction by precipitation 
with trichloroacetic acid followed by PAGE in the 
presence of 0.1% (w/v) SDS (fig.1). The active 
renin preparation contained both labelled renin 
(Peak I; Mr 41000) and a smaller component (Peak 
II; M, 17000) which we previously observed in 
preparations of renin [17]. The inactive renin 
preparation contained a single labelled polypeptide 
of Mr 49000. The labelled active and inactive renin 
were recovered from the gels in yields of 63 and 
73 % , respectively. 
A structural comparison of the two forms of 
renin was carried out by digestion of the labelled 
proteins with V8 proteinase followed by analysis of 
the digests by reverse-phase HPLC. Nine labelled 
peptides were resolved by HPLC ‘mapping’ of ac- 
tive renin (fig.2). Each of these peptides was also 
present in the digest of inactive renin, indicating 
that there are extensive regions of common se- 
quence in the two forms of the enzyme. The digest 
of inactive renin also contained three labelled pep- 
tides (III, IV and XI) which were not present in the 
digest of active renin. These data are clearly consis- 
tent with the hypothesis that inactive renin is a true 
renin zymogen. 
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